Endo at buy by Jefferies

Endo Pharmaceuticals Holdings, Inc. was rated by Jefferies & Co., Inc. analyst David Windley at a buy rating on news that Lidoderm had another strong quarter, helping offset weaker-than-expected oxycodone ER performance. Management reiterated revenue and earnings guidance for 2006. The company reported pro forma earnings per share of $0.58 (GAAP $0.54), four cents higher than Jefferies' estimate and consensus. Shares of the Chadds Ford, Pa., pharmaceutical company were up 58 cents, or 2.03%, at $29.19 on volume of 1,557,490 shares versus the three-month running average of 2,555,291 shares. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.